Cargando…

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases

The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of...

Descripción completa

Detalles Bibliográficos
Autores principales: Angotzi, Francesco, Visentin, Andrea, Scarmozzino, Federico, Cellini, Alessandro, Bertorelle, Roberta, Pizzi, Marco, Binotto, Gianni, Dei Tos, Angelo Paolo, Trentin, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947735/
https://www.ncbi.nlm.nih.gov/pubmed/35323322
http://dx.doi.org/10.3390/curroncol29030122
_version_ 1784674510345076736
author Angotzi, Francesco
Visentin, Andrea
Scarmozzino, Federico
Cellini, Alessandro
Bertorelle, Roberta
Pizzi, Marco
Binotto, Gianni
Dei Tos, Angelo Paolo
Trentin, Livio
author_facet Angotzi, Francesco
Visentin, Andrea
Scarmozzino, Federico
Cellini, Alessandro
Bertorelle, Roberta
Pizzi, Marco
Binotto, Gianni
Dei Tos, Angelo Paolo
Trentin, Livio
author_sort Angotzi, Francesco
collection PubMed
description The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of rare neoplasms that arise along with CLL may hinder the benefit that these therapies grant to patients. Moreover, the ability of newer therapies to alter the landscape of these complications is still largely unknown. Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions. Here, we report two unusual cases of PMF that occurred a few months after the start of therapy for CLL with targeted agents (ibrutinib and venetoclax). Both cases represented a diagnostic and therapeutic challenge, underscoring the need for clinicians to remain vigilant about the possible co-occurrence of these two hematological malignancies, especially in the era of targeted therapy for CLL.
format Online
Article
Text
id pubmed-8947735
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89477352022-03-25 Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases Angotzi, Francesco Visentin, Andrea Scarmozzino, Federico Cellini, Alessandro Bertorelle, Roberta Pizzi, Marco Binotto, Gianni Dei Tos, Angelo Paolo Trentin, Livio Curr Oncol Case Report The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of rare neoplasms that arise along with CLL may hinder the benefit that these therapies grant to patients. Moreover, the ability of newer therapies to alter the landscape of these complications is still largely unknown. Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions. Here, we report two unusual cases of PMF that occurred a few months after the start of therapy for CLL with targeted agents (ibrutinib and venetoclax). Both cases represented a diagnostic and therapeutic challenge, underscoring the need for clinicians to remain vigilant about the possible co-occurrence of these two hematological malignancies, especially in the era of targeted therapy for CLL. MDPI 2022-02-27 /pmc/articles/PMC8947735/ /pubmed/35323322 http://dx.doi.org/10.3390/curroncol29030122 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Angotzi, Francesco
Visentin, Andrea
Scarmozzino, Federico
Cellini, Alessandro
Bertorelle, Roberta
Pizzi, Marco
Binotto, Gianni
Dei Tos, Angelo Paolo
Trentin, Livio
Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title_full Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title_fullStr Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title_full_unstemmed Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title_short Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
title_sort primary myelofibrosis occurring during targeted therapy for chronic lymphocytic leukemia: a report of two cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947735/
https://www.ncbi.nlm.nih.gov/pubmed/35323322
http://dx.doi.org/10.3390/curroncol29030122
work_keys_str_mv AT angotzifrancesco primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT visentinandrea primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT scarmozzinofederico primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT cellinialessandro primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT bertorelleroberta primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT pizzimarco primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT binottogianni primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT deitosangelopaolo primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases
AT trentinlivio primarymyelofibrosisoccurringduringtargetedtherapyforchroniclymphocyticleukemiaareportoftwocases